Zhe Li

Title: Zhe Li: Innovator in CAR T Cell Therapy

Introduction

Zhe Li is a prominent inventor based in Burlingame, CA (US). He has made significant contributions to the field of immunotherapy, particularly in the development of innovative chimeric antigen receptors (CARs) for cancer treatment. His work focuses on enhancing the efficacy of CAR T cell therapy through novel mechanisms.

Latest Patents

Zhe Li holds a patent for a groundbreaking invention titled "Protease-activating CD45-gate CAR." This invention features a reversibly gated effector polypeptide that includes an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. The patent also encompasses nucleic acids, including vectors and expression vectors that encode the protease-activating CD45-gate CAR, as well as immune cells such as T cells that express these nucleic acids. The invention outlines methods for treating various forms of cancer by administering CAR T cell therapy, where the CD45 gate inhibits activation until exposed to a specific protease.

Career Highlights

Throughout his career, Zhe Li has worked with leading companies in the biotechnology sector. Notably, he has been associated with Allogene Therapeutics, Inc. and Pfizer Corporation. His experience in these organizations has allowed him to contribute to cutting-edge research and development in cancer therapies.

Collaborations

Zhe Li has collaborated with notable professionals in his field, including Shanshan Lang and Thomas John Van Blarcom. These collaborations have further enriched his research and innovation efforts.

Conclusion

Zhe Li's contributions to CAR T cell therapy exemplify the impact of innovative thinking in the fight against cancer. His patented technology represents a significant advancement in immunotherapy, showcasing the potential for improved treatment outcomes.